Featured Research

from universities, journals, and other organizations

Inhaling hypertonic saline decreases hospital admissions in children with bronchiolitis

Date:
May 26, 2014
Source:
Children's Hospital Los Angeles Saban Research Institute
Summary:
Infants with bronchiolitis who were treated with inhaled hypertonic saline in the emergency department (ED) were less likely to require admission to the hospital compared to infants treated with normal saline. Bronchiolitis is a respiratory infection common in infants and young children that results in approximately 150,000 hospitalizations each year, with an estimated cost of $500 million.

This is Susan Wu, M.D.
Credit: The Saban Research Institute

A team of researchers, led by physicians from Children's Hospital Los Angeles, have found that infants with bronchiolitis who were treated with inhaled hypertonic saline in the emergency department (ED) were less likely to require admission to the hospital compared to infants treated with normal saline.

The study, conducted at Children's Hospital Los Angeles and UCSF Benioff Children's Hospital Oakland, will be published in JAMA Pediatrics on May 26.

Bronchiolitis is a respiratory infection common in infants and young children that results in approximately 150,000 hospitalizations each year, with an estimated cost of $500 million.

"Previous studies have shown positive effects of using hypertonic saline, a concentrated salt solution, on infants and young children with bronchiolitis," said lead author, Susan Wu, MD, with The Saban Research Institute of Children's Hospital Los Angeles. "What is unique about this study is that we looked at the effect of administering hypertonic saline in the ED and then considered its effect on hospital admission."

The investigators treated 408 babies and young children; 197 received normal saline and 211 received 3% hypertonic saline. Patients were treated with their assigned intervention up to three times in the ED. Those admitted continued to receive the therapy every eight hours until discharge.

Investigators found that 42.6% of patients treated with normal saline required hospital admission compared with 28.9% of patients treated with hypertonic saline.

"We found that infants and young children with bronchiolitis treated with nebulized hypertonic saline in the ED were less likely to require hospitalization," said Wu, who is also an assistant professor of Clinical Pediatrics at the Keck School of Medicine of the University of Southern California. "It's gratifying to find an inexpensive yet effective therapy that helps patients while also reducing the cost of healthcare."


Story Source:

The above story is based on materials provided by Children's Hospital Los Angeles Saban Research Institute. Note: Materials may be edited for content and length.


Journal Reference:

  1. Susan Wu, Chris Baker, Michael E. Lang, Sheree M. Schrager, Fasha F. Liley, Carmel Papa, Valerie Mira, Ara Balkian, Wilbert H. Mason. Nebulized Hypertonic Saline for Bronchiolitis. JAMA Pediatrics, 2014; DOI: 10.1001/jamapediatrics.2014.301

Cite This Page:

Children's Hospital Los Angeles Saban Research Institute. "Inhaling hypertonic saline decreases hospital admissions in children with bronchiolitis." ScienceDaily. ScienceDaily, 26 May 2014. <www.sciencedaily.com/releases/2014/05/140526182644.htm>.
Children's Hospital Los Angeles Saban Research Institute. (2014, May 26). Inhaling hypertonic saline decreases hospital admissions in children with bronchiolitis. ScienceDaily. Retrieved July 24, 2014 from www.sciencedaily.com/releases/2014/05/140526182644.htm
Children's Hospital Los Angeles Saban Research Institute. "Inhaling hypertonic saline decreases hospital admissions in children with bronchiolitis." ScienceDaily. www.sciencedaily.com/releases/2014/05/140526182644.htm (accessed July 24, 2014).

Share This




More Health & Medicine News

Thursday, July 24, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

New Painkiller Designed To Discourage Abuse: Will It Work?

New Painkiller Designed To Discourage Abuse: Will It Work?

Newsy (July 24, 2014) The FDA approved Targiniq ER on Wednesday, a painkiller designed to keep users from abusing it. Like any new medication, however, it has doubters. Video provided by Newsy
Powered by NewsLook.com
Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Newsy (July 24, 2014) Sheik Umar Khan has treated many of the people infected in the Ebola outbreak, and now he's become one of them. Video provided by Newsy
Powered by NewsLook.com
Condemned Man's US Execution Takes Nearly Two Hours

Condemned Man's US Execution Takes Nearly Two Hours

AFP (July 24, 2014) America's death penalty debate raged Thursday after it took nearly two hours for Arizona to execute a prisoner who lost a Supreme Court battle challenging the experimental lethal drug cocktail. Duration: 00:55 Video provided by AFP
Powered by NewsLook.com
China's Ageing Millions Look Forward to Bleak Future

China's Ageing Millions Look Forward to Bleak Future

AFP (July 24, 2014) China's elderly population is expanding so quickly that children struggle to look after them, pushing them to do something unexpected in Chinese society- move their parents into a nursing home. Duration: 02:07 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins